NCT01516749View on ClinicalTrials.gov

Anakinra as a Treatment for Hydradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2013

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

anakinra

Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.

Trial Locations (1)

94110

San Francisco General Hospital, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT01516749 - Anakinra as a Treatment for Hydradenitis Suppurativa | Biotech Hunter | Biotech Hunter